Coadministration Of Fluvastatin And Ezetimibe In Acute Coronary Syndrome

Objective:To evaluate lipid-lowering effects of fluvastatin40 mg coadministration with ezetimibe 10mg in patients with acute coronary syndrome. and the change on high sensitivie C-reactive protein. Methods:92 patients with acute coronary syndrome were divided randomly into two groups:observed group in 44 coadministrated fluvastatin40 mg with ezetimibe 10 mg daily, control group in 48 administrated with fluvastatin 40 mg daily in 7 days. detected their lipid and high sensitivie C-reactive protein at day 0, days3and days 7. Comparative Analysis were made after treatment in and between groups. Results: When compared with baseline,TC, LDL-C and ApoB decreased significantly in all two groups at days 7(P<0.05), TG only decreased significantly in observed group (P<0.01); TC,LDL-C and TG decreased further in all two groups at days 7 (P<0.01), but ApoB kept no changed in control group, while decreased further in observed group, VLDL produced significant decrease in observed groups(P<0.05), HDL-C ApoAl elevated significantly in control group(P<0.05). When compared between two groups, observed group produced greater reduction than control group at days 3 in TC(-12.90%vs-8.29% P<0.05),LDL-C(-15.5%vs-4.5%P<0.05), and the there was more significant after 7days, TC(-23.8%vs-18.7%P＜0.05), LDL-C(-24.8%vs-9.7%P＜0.01); and there was difference between two groups in reducation of ApoB(-22.7%vs-5.47%P＜0.05); HDL-C,VLDL,VLDL and Lp(a) had improved at days 7 in all groups, but hadn't produce significant difference, in term of either chinese guidelines on prevention and treatment of dyslipidemia in adults goal LDL-C<2.07mmol/L or NCEP ATP III goal LDL-C<1.8mmol/L, observed group had more reduction than control group after at days 7 (57%vs21%P＜0.05) and (48%vsl6.7%P＜0.05). When compared with baseline, hs-CRP reduced in all two groups at days 7(P<0.05), and got further reduction in days 7(P<0.05); but produced significant difference in at days 7 (1.25(1.85)vs2.35(2.65) P<0.05), observed group had more reduction. No adverse effect of hepatotoxicity or myopathy in all two groups in trial. Conclusion:When treatment of patients with acute coronary syndrome, coadministration fluvastatin 40mg with ezetimibe 10mg is superior to fluvastatin 40mg alone in lowering LDL-C,TC, allow more patients reached LDL-C goal, and has better anti-inflammation effects.